对腺病毒载体 COVID-19 疫苗接种后血小板减少症和血栓形成的不良反应的担忧。
Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination.
机构信息
Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
出版信息
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211040110. doi: 10.1177/10760296211040110.
Since the outbreak of Covid-19 in December, 2019, scientists worldwide have been committed to developing COVID-19 vaccines. Only when most people have immunity to SARS-CoV-2, COVID-19 can reduce even wholly overcome. So far, nine kinds of COVID-19 vaccines have passed the phase III clinical trials and have approved for use. At the same time, adverse reactions after COVID-19 vaccination have also reported. This paper focuses on the adverse effects of thrombosis and thrombocytopenia caused by the COVID-19 vaccine, especially the adenovirus-vector vaccine from AstraZeneca and Pfizer, and discusses its mechanism and possible countermeasures.
自 2019 年 12 月新冠疫情爆发以来，全球科学家一直致力于研发 COVID-19 疫苗。只有当大多数人对 SARS-CoV-2 具有免疫力时，COVID-19 才能得到减轻甚至完全克服。迄今为止，已有九种 COVID-19 疫苗通过了 III 期临床试验并获得了使用批准。同时，COVID-19 疫苗接种后的不良反应也有报道。本文重点关注 COVID-19 疫苗引起的血栓和血小板减少症的不良反应，特别是阿斯利康和辉瑞的腺病毒载体疫苗，并讨论其机制和可能的对策。
Zotero 插件